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ABSTRACT 
Lycopene is a widely used nutraceuticals for its antioxidant property but the molecule has poor aqueous solubility, high instability, and 
extremely low intestinal permeability leading to its poor bioavailability. In the present study, pre-formulation study was carried out to prepare 
sodium alginate microbeads with the intention to deliver an effective amount of lycopene for high absorption through oral route. A thorough 
physical characterization and spectral analysis were done to understand the characteristic of lycopene such as its melting point, UV 
spectrophotometric analysis, chromatography through reverse phase HPLC. Fourier transform infrared spectroscopy and differential scanning 
calorimetry were adopted to know the interaction of sodium alginate with lycopene. Box-Behnken design (version 9.0.2.0, Stat Ease Inc, USA) 
was used to analyse the effect of formulation variables such as sodium alginate (%), glutaraldehyde (%) and stirring speed on lycopene 
entrapment and its loading into microbeads. The adopted preformulation strategy revealed that lycopene was a crystalline powder with a 
sharp melting point at 155oC and the prominent functional groups were present in the sample. UV and HPLC analysis revealed precise 
quantitation and authenticity of lycopene. Excipient compatibility also revealed inertness of sodium alginate. Response surface morphology 
revealed significant effect of alginate, glutaraldehyde and stirring speed on formation of best composition. Therefore, it is concluded that 
lycopene can be formulated as microbeads for oral drug delivery. 
Keywords: lycopene, sodium alginate, permeation, absorption, microbeads 
 
Article Info: Received 10 July 2019;     Review Completed 13 Aug 2019;     Accepted 19 Aug 2019;     Available online 30 Aug 2019 
Cite this article as: 
Rahman S, Amin S, Mir SR, Kohli K, Pre-Formulation Study for Palatable Microbeads of Lycopene, Journal of Drug Delivery 
and Therapeutics. 2019; 9(4-A):320-327  http://dx.doi.org/10.22270/jddt.v9i4-A.3484                                                         
*Address for Correspondence:  
Dr. Saima Amin, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New 
Delhi, India 
 
 
INTRODUCTION 
Oral drug delivery is considered as an attractive and most 
preferred route for drug administration as it provides some 
advantages for patients, such as the ease of drug 
administration and a high degree of flexibility on dosages. In 
oral administration, drugs should be protected under 
unstable biological environments including drug 
degradation induced by the GI tract and first-pass liver 
effects after oral administration before reaching the targeted 
sites 1.  
Most of the drugs exhibit inconsistent gastrointestinal 
absorption, thereby resulting in unsatisfactory therapeutic 
efficacy which can be attributed to their inadequate 
solubility in vivo 2.  Besides poor solubilisation of drug in the 
gastrointestinal tract (GIT), there are multiple other factors 
which reduce the degree of absorption of poorly soluble 
drugs. Several lipophilic drugs are candidates for efflux 
transporters such as P-glycoprotein which further leads to 
their poor in vivo prospect 3,4. Therefore, there is a 
substantial call for an ideal microencapsulation system 
which takes into accounts all these aspects and subsequently 
fills the loopholes for enhanced deliverance of lipophilic 
drugs. In this regard sodium alginate microbeads are a 
promising formulation approach as they have the potential 
of fixing these predicaments by increasing the stability and 
life of the drug being encapsulated, facilitate the 
manipulation of the drug and control its liberation in an 
adequate time and space further improving and normalizing 
the absorption of such drugs 4. 
Lycopene, a phytonutrient belongs to the family of acyclic 
carotenoids 5,6 and is responsible for the red colour in 
tomato and its potent antioxidant 7. This attributes to the 
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prevention of certain types of cancer, cardiovascular 
diseases, hyperlipidaemia, etc. 8. A great interest has recently 
been focused on lycopene due to its preventive activity 
against several pathologies, such as cardiovascular disease9, 
hepatic fibrogenesis10, solar light induced erythema 11, 
human papillomavirus persistence 12 and some cancer types, 
such as prostate, gastrointestinal and epithelial13. Lycopene 
has also been recently reported to play a role in lung 
function 14 as well as in foetal growth 15.  
Despite the tremendous health benefits, poor aqueous 
solubility, low bioavailability, high instability and extremely 
low intestinal permeability are the frightening challenges for 
clinical utility of lycopene 16,17. Besides, in certain health 
disorders, the demand of high therapeutic dose of lycopene 
is still remained a challenge for conventional dosage forms. 
Therefore, a well-organized delivery system is indeed 
warranted to enhance oral bioavailability and therapeutic 
effectiveness of lycopene. Therefore, in the present work we 
studied the pre-formulation aspects of sodium alginate 
microbeads. 
MATERIAL AND METHODS 
Material  
Lycopene of purity 6% was obtained from Bio-ethical 
Pharmaceutical Ltd., Baddhi, India and sodium alginate 
(216.12 g/mol), glutaraldehyde (25% w/v) solution, 
acetonitrile (HPLC grade), tetrahydrofuran (HPLC grade), 
methanol (HPLC grade) and n-hexane (HPLC grade) were all 
purchased from s.d. Fine Chemicals, Mumbai, India.  
Method  
Physical characterization and identification of drug  
Lycopene was evaluated for physical characteristics such as 
appearance, odour and melting point. 
Spectral analysis 
FT-IR spectral analysis  
FTIR spectrum of lycopene was taken by Tensor II FTIR- 
Spectrophotometer (Bruker, USA). Lycopene was scanned at 
the rate of 4 mm/s and a resolution of 2 cm-1 between wave 
number ranging from 4000 cm-1 to 650 cm-1.  
Ultraviolet spectral analysis  
For the purpose of quantification of lycopene at various 
stages of formulation development and characterization, UV- 
Visible spectrophotometry was used. For UV-Visible 
spectroscopic analysis of lycopene, the standard plot for 
lycopene in n-hexane was prepared using Shimadzu UV- 
1601 spectrophotometer (Shimadzu Corp, Kyoto, Japan). 2 
mg lycopene was accurately weighed and dissolved in n-
hexane and volume was made up to 10 ml to obtain 100 
μg/ml stock solution. It was scanned with UV- Spectrometer 
between 200nm to 800nm. The calibration plot was 
prepared in the concentration range 10-90 μg/ml. 
HPLC analysis 
A simple and sensitive RP- HPLC method was developed to 
assure the purity of the lycopene sample. The HPLC system 
comprised of a binary pump having UV detector (Shimadzu, 
Japan), C-18 column (150 mm × 4.6 mm) particle size 5 μm 
(Agilent, Switzerland) as an analytical column. The mobile 
phase consisted of acetonitrile and tetrahydrofuran (50:50 
% v/v). The flow rate was maintained at 1 mL min-1. 5mg 
lycopene was accurately weighed and dissolved in 
acetonitrile and volume was made up to 25 ml to obtain a 
stock 200 μg/ml concentration. From the stock different 
dilutions ranging from 10-200 μg/ml were prepared using 
acetonitrile as diluting medium. Samples were filtered 
through a 0.25 μm filter (Axiva Sichem Biotech, Delhi, India) 
and injected by a 20 μL loop injector. Detection was carried 
out at a wavelength of 479 nm. Data and chromatogram 
were obtained using Class-VP software.  
Solubility study 
2 mg of lycopene was dissolved in 10mL of simulated gastric 
fluid of pH 1.2 and simulated intestinal fluid of pH6.8 and 
was scanned through UV. The samples were then incubated 
with equal volume of n-hexane for a period 3h. The samples 
were scanned from 200-800 to observe the wavelength 
related to identity of lycopene. The amount of drug extracted 
in n-hexane was estimated through the calibration plot 
prepared in n-hexane.  
Drug excipient compatibility study 
The mixture of lycopene and sodium alginate in the ratio 1:1 
was stored in glass vials for 7 days at 25oC and 60% relative 
humidity. The samples were analysed for any physical or 
chemical changes. 
Statistical optimization of developed formulation by 
response surface methodology  
In order to get optimized formulation with best % 
entrapment efficiency and % drug loading, a three factor 
three level Box-Behnken design (version 9.0.2.0, Stat Ease 
Inc, USA) was used. The response surface methodology 
consisted of 3 factors: sodium alginate (%) (X1), 
glutaraldehyde (%) (X2), and stirring speed (rpm) (X3) 
tested at 3 levels: low, medium and high levels represented 
as -1, 0,+1, respectively. Dependent variables for the study 
were % encapsulation efficiency (Y1) and % drug loading 
(Y2) respectively. 17 experimental runs were obtained and 
analysed for the influence of the variables (Table 1).  
RESULTS AND DISCUSSION 
Lycopene is a red colour component extracted from 
tomatoes, watermelon and other fruits. Till date, a lot of 
research has been done to prove its antioxidant property but 
a successful dosage form for such a health supplement is not 
available. Though solid lipid nanoparticles, protein 
nanoparticles etc. are available at research level but the 
problems related to its poor bioavailability and thorough 
elucidation of its mechanism of action through such dosage 
forms, is missing. In the present research work, sodium 
alginate microbeads were envisaged to deliver an effective 
amount of lycopene for high absorption per oral. To begin 
the research work, lycopene provided as gift sample was 
characterized for its physical attributes such as colour, 
nature of the powder and melting point. The provided 
sample showed presence of unsaturation bonds and straight 
chain configuration as supported by FTIR spectrum (Figure 
1). Major peaks of the spectrum with characteristics peak at 
2972.09, 2865.80, 1540.25 cm-1 corresponding to C-H bond, 
=C⎯CH3 bond, and C=C bond respectively were interpreted to 
determine the respective functional groups present. To 
authenticate the spectrum, FTIR spectrum of the extracted 
lycopene reported by Lopez-Cervantes et al 18 was compared 
with lycopene sample. The spectrum revealed the true 
identity of lycopene as reported in literature 19  
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Figure 1: FTIR for lycopene as reported in literature and the sample procured. 
 
Lycopene did not show solubility in solvents such as water, 
buffer of pH 1.2 and 6.8, methanol and ethanol. Therefore, it 
was decided to adopt incubation method for estimation of 
lycopene. The amount of lycopene (1mg) was placed in 
buffer pH 1.2 and 6.8. After thorough stirring and vortexing, 
the sample did not show solubility. It was then treated with 
equal volume of n-hexane. After vortexing, the sample (n-
hexane) turned slight orange due to presence of lycopene. 
The sample in n-hexane was scanned for max at 471 nm 
(Figure 2). Since the initial sample was transparent with 
lycopene granules floating on the surface, but with n-hexane 
the colour developed. Thus it was observed that lycopene 
partitioned to n-hexane phase completely and was 
estimated. Therefore, standard plot of lycopene was 
prepared in n-hexane. The component showed good 
linearity (R2=0.995) between concentration of analyte and 
the absorbance at 471 nm (Figure 2)20. 
 
 
Figure 2: UV Spectrum of lycopene and calibration plot prepared in n-hexane. 
HPLC method of analysis was also reproduced for estimation 
of lycopene 21. HPLC analysis of the lycopene showed 
linearity in the range 10-200 μg/ml with retention time 
3.683  0.25 min at wavelength 479 nm.  The chromatogram 
and the calibration plot for concentrations detected are 
shown in Figure 3. 
 
 
Figure 3: HPLC chromatogram and calibration plot of lycopene 
A compatibility study was done to examine the physical and 
chemical interaction between lycopene and sodium alginate 
used in the formulation. There was no notable change in the 
samples when observed visually. No change in colour and 
odour was observed. Physical changes like liquefaction and 
change in weight were also not observed. Lycopene 
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exhibited an endothermic peak at 155.499 oC due to its 
melting. It revealed the crystalline nature of the provided 
small granules of lycopene 22 (Figure 4). Sodium alginate 
likely to be used in microbeads exhibited 3 sharp 
endothermic peaks i.e. at 100 C, 250 C and 340-410 C 
(Figure 4) in DSC 23. The first peak was due to release of 
water while the second and third were attributed to 
decomposition of polymer to respective carbonates which 
melted at high temperature. DSC analysis of the mixture was 
also performed (Figure 4) which indicated absence of peak 
due to lycopene which was due released water that might 
have interacted with lycopene leading to its instability and 
absence of its endothermic peak (155 C) 23. 
  
 
Figure 4: DSC thermogram of lycopene (A), sodium alginate (B) and physical mixture (C) 
The selected independent variables for optimization of response influenced the % entrapment efficiency and % drug loading 
efficiency which is evident from the result reported in Table 1.  
 
Table 1: Box-Behnken experimental design for optimization of lycopene sodium alginate beads 
Exp. 
run 
Sodium Alginate (%) 
(A) 
Glutaraldehyde 
(%)                (B) 
Stirring speed 
(rpm) (C) 
Encapsulation 
Efficiency % 
Drug Loading 
% 
R1 3.5 0.5 300 19.42 6.94 
R2 3.5 0.75 250 27.54 6.03 
R3 3 0.75 200 10.241 6.99 
R4 4 0.5 250 31.287 5.58 
R5 3 0.625 300 3.8 6.16 
R6 3 0.5 250 2.87 6.1 
R7 3.5 0.5 200 19.42 6.94 
R8 4 0.625 200 6.49 5.53 
R9 3.5 0.625 250 10.08 7.04 
R10 3.5 0.625 250 10.08 7.04 
R11 4 0.625 300 6.49 5.53 
R12 3.5 0.625 250 10.08 7.04 
R13 3.5 0.625 250 10.08 7.04 
R14 4 0.75 250 5.245 5.49 
R15 3.5 0.75 300 10.241 6.99 
R16 3 0.625 200 3.8 6.16 
R17 3.5 0.625 250 10.08 7.04 
 
The ability of micrbeads to entrap the drug is the 
determining factor for selection of the method of 
preparation and composition of the beads. The effect of 
sodium alginate on the entrapment efficiency was optimized. 
The % drug entrapment of lycopene microbeads were 
obtained in the varying range from 3.8 to 31.287%. Different 
statistical tools such as sum of square value, mean square 
value, F-value, p-value, PRESS (prediction sum of squares) 
values and adequate precision value, test of ANOVA, R2 value 
on linear, quadratic and cross product term effects of the 
above-mentioned variables were estimated in order to 
generate a mathematical relationship on the basis of 
coefficient of each factor with best fitting to the polynomial 
equation 24. The Model F-value of 9325.53 implied that 
quadratic model was significant. There was only a 0.01% 
chance that an F-value that large could occur due to noise. 
Values of "Prob > F" less than 0.0500 indicated model terms 
were significant. In this case A, B, AB, A2, B2, C2, A2B were 
significant model terms. Values greater than 0.1000 
indicated the model terms were not significant. Summary of 
this observation is given in Table 2 
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Table 2: Statistical analysis for entrapment efficiency 
 
Sum of 
 
Mean F p-value 
 
Source Squares df Square Value Prob > F 
 
Model 1069.65 10 106.96 9325.53 < 0.0001 significant 
A-Sodium alginate 16.54 1 16.54 1441.75 < 0.0001 
 
B-Glutaraldehyde 84.25 1 84.25 7345.55 < 0.0001 
 
C-Stirring speed 0.000 1 0.000 0.000 1.0000 
 
AB 642.93 1 642.93 56052.49 < 0.0001 
 
AC 0.000 1 0.000 0.000 1.0000 
 
BC 0.000 1 0.000 0.000 1.0000 
 
A2 9.66 1 9.66 842.55 < 0.0001 
 
B2 281.08 1 281.08 24505.70 < 0.0001 
 
C2 49.25 1 49.25 4293.60 < 0.0001 
 
A2B 36.07 1 36.07 3144.31 < 0.0001 
 
Residual 0.069 6 0.011 
   
Lack of Fit 0.069 2 0.034 
   
Pure Error 0.000 4 0.000 
   
Corr Total 1069.72 16 
    
 
The “Pred R-Squared” of 0.9974 was in reasonable 
agreement with the “Adj R-Squared” of 0.9998; i.e. the 
difference was less than 0.0024. The model proposed the 
following polynomial equation for % drug entrapment 
% Encapsulation efficiency = +10.08 +1.44A – 4.59B + 0.000C – 
12.68AB + 7.448E- 016AC + 5.380E – 016BC – 1.52A2 +8.17B2 -
3.42C2 +4.25A2B 
From the above equation it was inferred that % drug 
entrapment efficiency increased with increasing sodium 
alginate % (A) concentration.  At higher alginate 
concentrations, viscosity increased leading to a less diffuse 
matrix structure that hindered the drug escape from the 
core. Entrapment efficiency decreased with increase in 
glutaraldehyde % (B) as it might have affected the swelling 
of the alginate. The decrease in stirring speed resulted in 
increase in drug entrapment due to greater time provided 
for polymer swelling (Figure 5).  
For the effect of formulation variables on drug loading (%), 
again all statistical parameters were estimated in order to 
generate a mathematical relationship on the basis of 
coefficient of each factor with best fitting to the polynomial 
equation (Table 3). The Model F-value of 796.48 implied that 
the model was significant. There was only a 0.01% chance 
that an F-value that large could occur due to noise. Values of 
"Prob > F" less than 0.0500 indicated model terms were 
significant. In this case A, A2, B2, A2B were significant model 
terms. Values greater than 0.1000 indicated the model terms 
were not significant. If there are many insignificant model 
terms, model reduction would improve the model. The 
summary of this observation is given in Table 3. 
 
Table 3: Statistical analysis for % drug loading 
 
 
Sum of 
 
Mean F p-value 
 
Source Squares df Square Value Prob > F 
 
Model 6.64 10 0.66 796.48 < 0.0001 significant 
A-Sodium alginate 0.67 1 0.67 807.36 < 0.0001 
 
B-Glutaraldehyde 2.500E-003 1 2.500E-003 3.00 0.1340 
 
C-Stirring speed 0.000 1 0.000 0.000 1.0000 
 
AB 1.000E-004 1 1.000E-004 0.12 0.7409 
 
AC 0.000 1 0.000 0.000 1.0000 
 
BC 0.000 1 0.000 0.000 1.0000 
 
A2 5.86 1 5.86 7035.28 < 0.0001 
 
B2 0.015 1 0.015 18.19 0.0053 
 
C2 9.474E-004 1 9.474E-004 1.14 0.3273 
 
A2B 8.450E-003 1 8.450E-003 10.14 0.0190 
 
Residual 5.000E-003 6 8.333E-004 
   
Lack of Fit 5.000E-003 2 2.500E-003 
   
Pure Error 0.000 4 0.000 
   
Cor Total 6.64 16 
    
The “Pred R-Square” of 0.9699 was in reasonable agreement with the “Adj R-Squared” of 0.9980; i.e. the difference was less 
than 0.0281. The model proposed the following polynomial equation for % drug entrapment 
% drug loading = +7.04 - 0.29A + 0.025B + 0.000C - 5.000E -003AB + 1.911E- 017AC -5.270E – 017BC – 1.18A2 -0.060B2 -0.015C2 -
0.065A2B 
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From the above equation it was inferred that % drug loading 
increased with increasing sodium alginate % (A) as sodium 
alginate beads provided greater surface area for the loaded 
drug. Drug loading decreased with increase in 
glutaraldehyde % (B) concentration perhaps due to high 
polymer content that might have hindered the homogeneous 
distribution of glutaraldehyde leading to the formation of 
particles with reduced drug content 25. Drug loading 
decreased with decrease in stirring speed. Since the viscosity 
of the polymeric solution increased with high polymer 
concentration, low stirring speed was incapable of loading 
the drug on micrbeads (Figure 6). 
 
 
 
Figure 5:  (a) Linear correlation plot between actual and predicted value and (b), (c), and (d) 3D response surface plot 
showing effect of independent variables on entrapment efficiency (%). 
 
 
 
 
 
 
 
(a) 
(c) 
(b) 
(d) 
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Figure 6: (a) Linear correlation plot between actual and predicted value and (b), (c), and (d) 3D response surface plot 
showing effect of independent variables on drug loading (%) 
 
CONCLUSION 
Lycopene is a lipophilic molecule which has poor 
bioavailability due to poor solubility. All its formulations are 
used as nutraceuticals which are not able to improve the 
bioavailability. In the present research, we carried out 
systematic pre-formulation study for preparation of sodium 
alginate microbeads that would result in improved 
bioavailability through prolonged adhesion to intestinal 
mucosa.  Novel lycopene microbeads were prepared by 
precipitation method which showed higher drug entrapment 
and sufficient drug loading without incompatability with the 
polymer.  
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